JP5765634B2 - 低酸素活性化型プロドラッグを用いるがんの処置 - Google Patents

低酸素活性化型プロドラッグを用いるがんの処置 Download PDF

Info

Publication number
JP5765634B2
JP5765634B2 JP2011533309A JP2011533309A JP5765634B2 JP 5765634 B2 JP5765634 B2 JP 5765634B2 JP 2011533309 A JP2011533309 A JP 2011533309A JP 2011533309 A JP2011533309 A JP 2011533309A JP 5765634 B2 JP5765634 B2 JP 5765634B2
Authority
JP
Japan
Prior art keywords
cancer
administration
administered
combination
hap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011533309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506448A (ja
JP2012506448A5 (cg-RX-API-DMAC7.html
Inventor
ジェシカ サン，
ジェシカ サン，
ジョン ジー． クード，
ジョン ジー． クード，
ステュワート クロール，
ステュワート クロール，
マーク マッテウッチ，
マーク マッテウッチ，
チャールズ ピー． ハート，
チャールズ ピー． ハート，
チアン−シン デュアン，
チアン−シン デュアン，
Original Assignee
スレッシュホールド ファーマシューティカルズ， インコーポレイテッド
スレッシュホールド ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッシュホールド ファーマシューティカルズ， インコーポレイテッド, スレッシュホールド ファーマシューティカルズ， インコーポレイテッド filed Critical スレッシュホールド ファーマシューティカルズ， インコーポレイテッド
Publication of JP2012506448A publication Critical patent/JP2012506448A/ja
Publication of JP2012506448A5 publication Critical patent/JP2012506448A5/ja
Application granted granted Critical
Publication of JP5765634B2 publication Critical patent/JP5765634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011533309A 2008-10-21 2009-10-21 低酸素活性化型プロドラッグを用いるがんの処置 Active JP5765634B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US10725308P 2008-10-21 2008-10-21
US61/107,253 2008-10-21
US11836808P 2008-11-26 2008-11-26
US61/118,368 2008-11-26
US15070009P 2009-02-06 2009-02-06
US61/150,700 2009-02-06
US15116309P 2009-02-09 2009-02-09
US61/151,163 2009-02-09
US24417209P 2009-09-21 2009-09-21
US61/244,172 2009-09-21
PCT/US2009/061541 WO2010048330A1 (en) 2008-10-21 2009-10-21 Treatment of cancer using hypoxia activated prodrugs

Publications (3)

Publication Number Publication Date
JP2012506448A JP2012506448A (ja) 2012-03-15
JP2012506448A5 JP2012506448A5 (cg-RX-API-DMAC7.html) 2012-12-13
JP5765634B2 true JP5765634B2 (ja) 2015-08-19

Family

ID=42119663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533309A Active JP5765634B2 (ja) 2008-10-21 2009-10-21 低酸素活性化型プロドラッグを用いるがんの処置

Country Status (5)

Country Link
US (2) US8946275B2 (cg-RX-API-DMAC7.html)
EP (1) EP2350664B1 (cg-RX-API-DMAC7.html)
JP (1) JP5765634B2 (cg-RX-API-DMAC7.html)
ES (1) ES2884674T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010048330A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896040B1 (en) 2005-06-29 2012-08-01 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
MX2012014428A (es) 2010-07-12 2013-03-05 Threshold Pharmaceuticals Inc Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer.
KR20140038390A (ko) 2011-04-01 2014-03-28 쓰레솔드 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
WO2012142520A2 (en) * 2011-04-15 2012-10-18 Threshold Pharmaceuticals, Inc. Unit dose form for oral administration
JP2015500885A (ja) 2011-12-22 2015-01-08 スレッショルド ファーマシューティカルズ，インコーポレイテッド 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
EP2793899A4 (en) * 2011-12-22 2015-06-17 Threshold Pharmaceuticals Inc HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT
US20160045522A1 (en) * 2012-02-21 2016-02-18 Threshold Pharmaceuticals, Inc. Treatment of Cancer
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US10037382B2 (en) 2012-10-29 2018-07-31 Kyocera Corporation Surface acoustic wave sensor
US20160296538A1 (en) * 2013-04-10 2016-10-13 Threshold Pharmaceuticals, Inc. Predictive and response biomarker for th-302 anti-cancer therapy
WO2015013448A1 (en) 2013-07-26 2015-01-29 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CN104628772A (zh) * 2013-11-07 2015-05-20 四川恒康发展有限责任公司 一种抗肿瘤前药及其激活剂、组合物和应用
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US10131683B2 (en) 2014-07-17 2018-11-20 Molecular Templates, Inc. TH-302 solid forms and methods related thereto
SG11201707293VA (en) 2015-03-10 2017-10-30 Ascenta Pharmaceuticals Ltd Dna alkylating agents
BR112017021167A2 (pt) 2015-04-02 2018-07-03 Obi Pharma, Inc. composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i
WO2016210175A1 (en) 2015-06-24 2016-12-29 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
KR20190007017A (ko) * 2016-05-13 2019-01-21 테크리슨 리미티드 간 조직의 치료 방법
JP2019527236A (ja) * 2016-08-01 2019-09-26 モレキュラー テンプレーツ，インコーポレイティド 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
DK3565806T3 (da) 2017-01-06 2022-05-16 Rivus Pharmaceuticals Inc Nye phenylderivater
JP2019094284A (ja) * 2017-11-21 2019-06-20 日本化薬株式会社 ペメトレキセドを含有する注射用溶液製剤
CN109999183B (zh) * 2019-04-15 2021-03-09 中国科学技术大学 一种含有乏氧激活前药的纳米簇化酶及其制备方法和应用
JP7762796B2 (ja) 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
US20240366640A1 (en) * 2021-08-27 2024-11-07 Ascentawits Pharmaceuticals, Ltd. Lyophilized formulation solution and lyophilized formulation, and method and use thereof
CN118829436A (zh) 2022-03-15 2024-10-22 深圳艾欣达伟医药科技有限公司 治疗brca突变癌症患者的方法
US20250295677A1 (en) 2022-04-15 2025-09-25 Ascentawits Pharmaceuticals, Ltd. Method for treating cancer by using th-302 alone or in combination with parp inhibitor
WO2023226959A1 (zh) 2022-05-23 2023-11-30 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
WO2024061346A1 (zh) 2022-09-22 2024-03-28 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
WO2024179467A1 (zh) * 2023-02-27 2024-09-06 深圳艾欣达伟医药科技有限公司 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636195A (en) 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
EP0383492A3 (en) 1989-02-14 1991-08-07 Thoro System Products Inc. Dispersion system for rapid curing cement compositions
US5049132A (en) 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
JPH05507226A (ja) 1990-06-15 1993-10-21 コートラック・メディカル・インコーポレーテッド 薬物投与装置および方法
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6060083A (en) 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB9909612D0 (en) 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
AU5331300A (en) * 1999-06-11 2001-01-02 Henceforth Hibernia, Inc. Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions
EP1372717A2 (en) * 2001-03-23 2004-01-02 Aphton Corporation Combination treatment of pancreatic cancer
NZ521851A (en) 2002-10-08 2005-02-25 Auckland Uniservices Ltd Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
BRPI0416085A (pt) 2003-10-31 2007-01-02 Auckland Uniservices Ltd álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidos
WO2005086951A2 (en) 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
SE0400642D0 (sv) 2004-03-15 2004-03-15 Electrolux Ab Floor cleaning implement
AU2005309761A1 (en) 2004-11-22 2006-06-01 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer agents and prodrugs thereof
US20070117784A1 (en) 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
DE602006019074D1 (de) 2005-04-15 2011-02-03 Einstein Coll Med Vitamin k zur vorbeugung und behandlung von hautausschlag infolge einer anti-egfr-therapie
EP1896040B1 (en) * 2005-06-29 2012-08-01 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
EP1931769A2 (en) * 2005-10-03 2008-06-18 Genetix Pharmaceuticals Inc. Method for selectively depleting hypoxic cells
JP5596924B2 (ja) 2006-02-17 2014-09-24 カスケード プロドラッグ インコーポレイテッド ビンカアルカロイドｎ酸化物および類似体による過剰増殖疾患の処置
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
WO2008151253A1 (en) 2007-06-04 2008-12-11 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of antineoplastic agents
WO2009018163A1 (en) 2007-07-27 2009-02-05 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of anthracyclines
WO2009033165A1 (en) 2007-09-06 2009-03-12 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of bis-alkylating agents

Also Published As

Publication number Publication date
US20130202716A1 (en) 2013-08-08
EP2350664B1 (en) 2021-05-19
JP2012506448A (ja) 2012-03-15
ES2884674T3 (es) 2021-12-10
EP2350664A4 (en) 2014-04-30
US8946275B2 (en) 2015-02-03
US20150258125A1 (en) 2015-09-17
WO2010048330A1 (en) 2010-04-29
EP2350664A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
JP5765634B2 (ja) 低酸素活性化型プロドラッグを用いるがんの処置
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
EP2817011B1 (en) Treatment of cancer
TWI533866B (zh) 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途
JP2012506448A5 (cg-RX-API-DMAC7.html)
JP7193591B2 (ja) 化学療法の改善
CN102046187A (zh) 用于治疗癌症的方法和组合物
JP2021523169A (ja) ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法
WO2010086964A1 (ja) がん治療のための併用療法
TW201141473A (en) Combination therapy for small cell lung cancer
CN105283178A (zh) 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
US20170112807A1 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin c
CN103623394A (zh) 一种peg-hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
EP3463298B1 (en) Metronomic oral gemcitabine for cancer therapy
CN105263499A (zh) 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
HK1204956B (en) Treatment of cancer
AU2004251444A1 (en) Cancer treatment with epothilones
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1202423B (en) Combination therapy with a topoisomerase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150303

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150601

R150 Certificate of patent or registration of utility model

Ref document number: 5765634

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250